Law in the Internet Society

View   r5  >  r4  ...
BahradSokhansanjFirstPaper 5 - 28 Oct 2011 - Main.BahradSokhansanj
Line: 1 to 1
 
META TOPICPARENT name="FirstPaper"
Line: 15 to 15
 I don't really care about treatment of acute conditions -- while there will be some personalization, things like treatment of infectious diseases will still likely be a mass approach, though there may be more refined diagnostic procedures, which are significant (who will control them? this can just be collected at the hospital level). Indeed, drug companies don't care about them. All the money is in chronic diseases, and/or making acute into chronic, or "preventive" treatment, which is basically just chronic but pre-symptomatic.
Added:
>
>		Importance of chronic disease globally
 Prescription drug spending is a lot of money, but not all, and indeed what I'm talking about in terms of the future of medicine is a lot broader than drugs, because it also includes diagnostics and other kinds of physician "interventions" (and things like less ICU time) here is Kaiser's projected costs: Drug spending that is in 2009 approximately $250B more than doubling by 2020, driven by faster growth after a period of slower growth due to drugs coming off patents but with drugs having more exclusivity

Innovations happening now that are "open source" that I guess I have to talk about:


Revision 5r5 - 28 Oct 2011 - 15:10:25 - BahradSokhansanj
Revision 4r4 - 27 Oct 2011 - 21:07:22 - BahradSokhansanj
This site is powered by the TWiki collaboration platform.
All material on this collaboration platform is the property of the contributing authors.
All material marked as authored by Eben Moglen is available under the license terms CC-BY-SA version 4.
Syndicate this site RSSATOM